Abstract
Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: An Open-Label, Single-Arm, Multicenter Phase 2 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have